Amid repeated stumbles, Pfizer and Eli Lilly tout their anti-NGF pain drug tanezumab — but questions linger
Pfizer and Eli Lilly have started to make their late-stage case for tanezumab, outlining some positive results on pain but raising some serious issues about just how effective this low-dose pain drug could be.
According to their researchers, the drug, angling for the non-opioid market the feds want to promote, hit statistical significance against a placebo — scoring on 3 out of 3 primary endpoints.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.